Ricovir-l Tablet (Lamivudine (300mg) + Tenofovir disoproxil fumarate (300mg))

Ricovir-l Tablet is a combination of two antiretroviral medicines such as Lamivudine (300mg) and Tenofovir disoproxil fumarate (300mg). Doctor prescribes it in the treatment of HIV (human immunodeficiency virus) infection and manage or treat AIDS. It works by inhibiting the virus multiplication & boosting the immune system to fight against the infection. It should be taken with food in the exact dose as prescribed by the doctor.

HIV

Ricovir-l Tablet(Lamivudine 300mg and Tenofovir disoproxil fumarate 300mg) is a strong antiviral medicine that may show certain adverse while manageable impact on the body during the treatment. As these effects resolve on their own without any special medical attention. However, if you ever experience serious or unusual side effects contact your healthcare professional immediately.
Some common side effects of Ricovir-l Tablet include:
● Dizziness
● Nausea
● Diarrhea
● Tiredness
● Weakness
● Fever
● Insomnia (difficulty in sleeping)
● Cough
● Depression

Doctor determines the exact dose and duration with Ricovir-l Tablet(Lamivudine 300mg and Tenofovir disoproxil fumarate 300mg) as per the overall health condition of the patient. This drug should be taken with food or after food, but at the fix time every day to get effective results. Don't miss a dose or overdose on the medicine. Swallow it as a whole with a glass of water and do not crush, chew, or open it.

● Gallant, J. E., & Deresinski, S. (2003). Tenofovir disoproxil fumarate. Clinical Infectious Diseases, 37(7), 944-950.
● Tibalinda, P., Pius, D., Shedafa, R., Masota, N., Temu, M., & Kaale, E. (2016). Pre-Formulation Development of Lamivudine 300 mg and Tenofovir Disoproxil Fumarate (TDF) 300 mg Fixed Dose Combination Tablets. Pharmacology & Pharmacy, 7(07), 247-254.
● Kearney, B. P., Flaherty, J. F., & Shah, J. (2004). Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clinical pharmacokinetics, 43(9), 595-612.
● Dravid, A., Betha, T. P., Sharma, A. K., Gawali, R., Mahajan, U., Kulkarni, M., ... & Rathod, N. (2020). Efficacy and safety of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV‐1‐infected subjects on nonnucleoside reverse transcriptase inhibitor‐containing first‐line antiretroviral therapy in Pune, India. HIV medicine, 21(9), 578-587.
● Kuo, A., Dienstag, J. L., & Chung, R. T. (2004). Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clinical Gastroenterology and Hepatology, 2(3), 266-272.